Furthermore, AS-IV’s cardioprotective effects in heart failure appear to be dose-dependent, as demonstrated by increased expression of nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE)-dependent genes, such as heme oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase 1 (NQO-1), and sulfiredoxin-1 (Srxn-1), with rising AS-IV concentrations in the oxygen-glucose deprivation model (Gu et al., 2015). This evidence concerns the gene NQO1 and heart failure.